NDAINTRAMUSCULARPOWDER
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIMAXIN is a fixed-dose combination of imipenem (a broad-spectrum beta-lactam antibiotic) and cilastatin (a renal dehydropeptidase inhibitor) administered intramuscularly as a powder for injection. It is indicated for serious infections caused by susceptible gram-positive, gram-negative, and anaerobic bacteria. Cilastatin prevents renal metabolism of imipenem, enabling effective systemic delivery.
LOE Approaching
As loss of exclusivity approaches, the brand team is likely consolidating and shifting focus to pipeline assets or generic line extensions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRIMAXIN offers limited career growth in commercial or clinical roles given its LOE status and legacy positioning. Opportunities are concentrated in operational efficiency, generic portfolio management, and market access—suitable for mid-career professionals seeking stability over high-growth launches.
Supply Chain ManagerManufacturing Engineer
Worked on PRIMAXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.